. 2024 Aug 27;19(8):e0309245. doi: 10.1371/journal.pone.0309245

Table 1. Comparison of CARiC9-20/19 CAR-T cells generated from healthy donors and cancer patients.

Disease		Healthy Donor	Patients	DLBCL1	DLBCL2	DLBCL3	CLL1	CLL2	CLL3	HL	MM
Copy Number		1.85–3.47	1.82–5.46	2.51	5.46	2.21	3.36	2.81	3.76	2.04	1.82
% of CAR ⁺		32.5–49.6	19.93–53.22	26.33	50.01	34.23	40.64	33.41	53.22	26.24	19.93
Fold Expansion		43.54–157.55	57.95–198.96	67.22	67.30	60.38	104.57	57.95	198.96	149.75	139.35
Cell Number (x10 ⁶ )		17.34–50.60	4.58–27.54	7.29	4.95	5.80	15.76	7.71	4.58	24.08	27.54
% of B Cells (CD19 ⁺ )		0.01–0.36	0–1.18	0.77	1.18	0.35	0	0	0.61	0	0
% of NK Cells (CD3 ^- , CD56 ⁺ )		0.04–0.27	0.02–2.69	0.06	2.69	0.63	0.03	0.02	0.02	0.08	0.05
% of Exhaustion Marker⁺ Cells	PD-1	0.40–1.96	0.96–7.80	5.35	4.15	4.16	0.96	2.42	6.01	1.70	7.80
	TIM-3	0.10–5.34	1.07–2.96	1.77	2.96	1.98	1.40	2.32	2.37	1.35	1.07
	LAG-3	0.90–7.00	2.36–22.82	9.88	12.38	22.82	3.24	4.03	2.55	2.36	2.56
% of Senescence Marker⁺ Cells	KLRG-1	2.24–14.61	2.83–14.70	11.80	14.70	8.20	2.83	4.15	6.06	4.05	5.33
% of Senescence Marker⁺ Cells	CD57	0.03–0.68	0.63–5.82	5.82	1.46	2.54	1.11	1.78	0.63	1.13	1.28
Potency (% of Raji cell lysis) (fresh cells, E/T = 5, 48 h)		89.74–95.38	98.96–99.88	99.66	99.7	99.7	99.88	99.45	99.07	98.96	99.42
Potency (% of Raji cell lysis) (frozen cells, E/T = 5, 48 h)		44.99–61.96	45.46–84.31	73.35	74.21	75.21	84.31	75.70	45.46	77.49	70.31

CAR-T cells generated from PBMCs of 6 healthy donors and 8 cancer patients were cultured in 24-well G-Rex for 10 days. The cell number of 24-well G-Rex culture is 50-times 50 less than a 1 L G-Rex culture (2.29×10⁸–1.38×10⁹ cells in 1 L G-Rex). DLBCL, diffuse large B-cell lymphoma; CLL, chronic lymphocytic leukemia; HL, Hodgkin lymphoma; MM, multiple myeloma.